Who is sponsoring NCT02300129?

NCT02300129 is sponsored by Galderma R&D.

What drugs are being tested in NCT02300129?

Interventions in NCT02300129: CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo, Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo, CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47, Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47.

Is NCT02300129 still recruiting?

NCT02300129 is currently completed. Last updated 29 August 2016.

Are results published for NCT02300129?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-08-29 · How we verify

NCT02300129

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of CD07805/47 Gel in Subjects Presenting With Flushing Related to Erythematotelangiectatic or Papulopustular Rosacea

Completed Phase 2 Results posted Last updated 29 August 2016

What this trial tests

Phase 2 trial testing CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo in Rosacea in 34 participants. Completed in 1 June 2014.

Timeline

1 April 2014

Primary endpoint
1 June 2014

1 June 2014

Quick facts

Lead sponsor	Galderma R&D
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	34
Start date	1 April 2014
Primary completion	1 June 2014
Estimated completion	1 June 2014
Sites	1 location across Germany

Drugs / interventions tested

CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo — full drug profile →
Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo — full drug profile →
CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47 — full drug profile →
Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47 — full drug profile →

Conditions studied

Rosacea — all drugs for Rosacea →

Sponsor

Galderma R&D — full company profile →

Who can join

18 and older, any sex, with Rosacea. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Total Number of Flushes for Each 2-week Period
Time frame: Day 22 and Day 36/Early termination

Sponsor's own description

Phase 2a study to assess the efficacy and safety of CD07805/47 0.5% gel in the prevention of the flush of rosacea.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Rosacea

Currently open trials in the same condition.

NCT07296497 — Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety · NA · recruiting
NCT06312813 — Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With · Phase 2 · recruiting
NCT06072066 — Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammatio · NA · recruiting
NCT05942248 — The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis · NA · recruiting
NCT05928169 — Determinants of Chronic Inflammatory Skin Disease Trajectories · recruiting

Other Galderma R&D trials

Trials by the same sponsor.

NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis · Phase 2 · recruiting
NCT07344584 — A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles · NA · not yet recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
NCT07398989 — A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin · Phase 4 · completed
NCT06988618 — Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02300129 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Galderma R&D
Last refreshed: 29 August 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02300129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing